PathGroup, one of the largest providers of anatomic pathology, digital pathology, clinical and molecular laboratory services in the United States, announced the acquisition of SkinDx, a leading dermatopathology laboratory in the Southeastern U.S., based in Birmingham, Alabama. This acquisition expands PathGroup’s presence in the dermatopathology space, while also providing state-of-the-art molecular pathology and clinical pathology services for current SkinDx clients. PathGroup is owned by Pritzker Private Capital along with management.
Discovery Life Sciences™ (Discovery), the biospecimen and biomarker specialists™, announced today that it has acquired Targos Molecular Pathology GmbH, Germany (Targos), one of the largest molecular pathology laboratories in Europe, to significantly expand its global tissue biomarker services. Targos represents another milestone in Discovery’s global expansion and complements its prior acquisition of Santa Barbara, Calif.-based QualTek Molecular Laboratories (QualTek), a leading North American immunohistochemistry (IHC) and biomarker development provider.
CellCarta, a global provider of precision medicine services, announced today the acquisition of Reveal Biosciences (“Reveal”), a San Diego California based computational pathology company offering cutting-edge artificial intelligence (AI)-based quantitative pathology and immunohistochemistry services to the biopharmaceutical industry. This acquisition further strengthens CellCarta’s position as a leading provider of histopathology biomarker services and will enable the company to broaden its offering in AI-enabled multi-omic data analysis services and applications.
StageBio, a leading provider of GLP-compliant necropsy, histology, pathology and specimen archiving services for both preclinical and clinical research, announced today its acquisition of TPL Path Labs of Freiburg, Germany. The combined organization offers an expanded array of histopathology, molecular pathology, toxicology, digital image analysis and related solutions to biopharma, medical device and academic researchers across the U.S., Europe and beyond. StageBio is a portfolio company of Ampersand Capital Partners.
UnitedHealthcare has issued new fee schedules to a number of Texas pathology groups in recent months, raising concerns that a broader effort to lower payment rates could be coming. The UHC action follows moves over the past year and a half by insurer Anthem to significantly cut payment rates for many pathology practices across the country and fits within a broader and long-term trend of public and private payors putting downward pressure on lab reimbursement. Joe Saad, chairman of pathology at Dallas-based Methodist Health System said that his practice received a letter this week from UHC laying out its new rates. He did not provide the new pricing but said that the insurer was “proposing a fee schedule that is very significantly different from the one that we had, and obviously much lower.”
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has completed the non-cash transaction of the transition of Oncometrix’s customer base, as discussed in Precipio’s recent announcement. As stated previously, the transaction with Poplar involves no exchange of cash or equity in consideration, providing non-dilutive impact to shareholders. “We are delighted to complete this transaction and partner with Precipio for the hematopathology business, enabling us to focus on our other core businesses”, said James Sweeney, CEO of Poplar Healthcare. “We look forward to continued collaboration with Precipio in other areas of our partnership”.
Synergy Laboratories (Synergy) announced today that it has acquired Mobile, Alabama-based Pathology Laboratory Associates (PLA) for an undisclosed price. The combination of PLA’s expertise in pathology and Synergy’s recognized leadership in the field of medical testing will enhance the care delivered to patients throughout the Southeast. PLA’s Vice-President, Dr. Kimberley V. Patterson, sees the combined organizations growing into a regional provider with an emphasis on women’s health. She explained, “We are excited about the opportunities to expand our capability to serve physicians and their patients with comprehensive out-patient laboratory and pathology services. We are especially interested in expanding our services related to women’s health to provide an Alabama-based source for quality, affordable laboratory services.”
StageBio has merged with Alize Pathology to form the leading provider of specialized histology, pathology, biomarker development, and archiving services for the biopharmaceutical, medical device and contract research industries. StageBio was recently created by the mergers of Histo-Scientific Research Laboratories (HSRL), Vet Path Services (VPS) and Tox Path Specialists (TPS), and now includes Alize Pathology. StageBio is a portfolio company of Ampersand Capital Partners. “Dr. Serge Rousselle, Dr. Joan Wicks and the Alize staff bring unique histopathology capabilities to StageBio. These services enable us to offer the industry an even broader range of highly specialized histopathology and imaging services,” said Mr. Thomas Galati, StageBio CEO. “We have successfully merged HSRL, VPS and TPS, and are excited to add Alize’s expertise to our growing list of offerings.”
PathGroup, one of the largest private providers of pathology, clinical and molecular laboratory services in the United States, announced today that Southeastern Pathology Associates has joined the PathGroup family of pathology practices and laboratories. The strategic combination adds to both organizations’ presence in the Southeast region, particularly in Georgia, where SEPA is headquartered, Florida and South Carolina. PathGroup previously acquired Pathologists Bio-Medical Laboratories (PBM) in 2019, a leading provider of pathology services in North Texas. Together, Nashville-based PathGroup and SEPA will include more than 175 pathologists representing every sub-specialty. This comprehensive pathology network will serve over 95 hospitals and thousands of physician practices across the United States, delivering quality diagnostic results and superior service levels. PathGroup is owned by Pritzker Private Capital along with management.
PHC Holdings Corporation (headquarters: Tokyo, Japan, hereafter PHCHD) announced Friday the completion of its acquisition of Anatomical Pathology business of Thermo Fisher Scientific Inc. (NYSE: TMO, hereafter Thermo Fisher) for approximately US$1.14 billion. The acquired Anatomical Pathology business will operate as a new stand-alone company named Epredia that will continue to serve as a leading global provider of comprehensive solutions in the anatomical pathology field, including microscope slides, instruments and consumables. PHCHD is a global healthcare company that offers value-added products and services across diabetes care, diagnostics, life sciences and healthcare IT. Through the acquisition of the Epredia business from Thermo Fisher, PHCHD will strengthen its diagnostics business by expanding its portfolio into oncology to support further business growth.
What We Do
Who We Are
How We Work
Who We Help
Get In Touch
Connect With Us
Subscribe to Our Daily Note
We publish a Daily Note that aggregates M&A activity, notable developments, regulatory changes, and conferences we deem to be of interest to our partners. It is a quick afternoon read and an easy way to keep your finger on the pulse of the healthcare space. Please fill in your name and email address below if you wish to subscribe.